Small Cap Stock Under Rs 50: Pharma Stock Jumps Post 44% Surge in Q4 Result | Do You Own?

Sudarshan Pharma Industries gained about 4% on 4 May, as investors reacted to strong Q4 numbers and a broad rally on Dalal Street. The small-cap pharma stock, priced below Rs 50, moved higher after the company reported sharp growth in both quarterly profit and revenue, along with solid full-year performance.

The company's March 2026 quarter net profit increased 44.8% to Rs 10.73 crore from Rs 7.41 crore a year earlier. Quarterly revenue also jumped, rising 36.72% to Rs 220.92 crore compared with Rs 161.59 crore in the March 2025 quarter. Analysts said these figures indicated firm operational traction across the business.

Sudarshan Pharma Industries share price and recent market performance

Sudarshan Pharma Industries' share price opened at Rs 31.40 per share on the BSE and hit that level as the intraday high. During the same session, the stock slipped to an intraday low of Rs 30.30. Sentiment was helped by the broader market, with the BSE Sensex climbing almost 1,000 points, or around 1.3%.

The stock's short-term record remains positive. Sudarshan Pharma Industries has gained 2.48% over the last week and 3.33% in the past two weeks. Over one month, the return stands at 16.94%. These moves show steady buying interest, especially after earnings, in a period of generally supportive market conditions.

Performance has been stronger over longer horizons. Over the previous three months, Sudarshan Pharma Industries has advanced 47.62%. Year-to-date, the stock is higher by 14.69%, while the six-month return is 8.20%. Over the last year, it has risen 16.28%, reflecting moderate but sustained progress for investors tracking the pharma segment.

Multi-year gains have been far larger. Over the last two years, Sudarshan Pharma Industries has delivered a multi-bagger return of 310.05%. Across three years, the gain is 345.40%. These figures highlight that, despite periods of volatility and operational hurdles, the stock has created notable long-term wealth for shareholders.

Sudarshan Pharma Industries share price, Q4 earnings and full-year numbers

Both quarterly and annual financials underline the uptrend. For the full financial year, Sudarshan Pharma Industries' net profit increased 55.64% to ₹23.30 crore from ₹14.97 crore in the prior year. Annual sales rose 39.21%, reaching ₹703.06 crore compared with ₹505.04 crore in the earlier fiscal period.

Sudarshan Pharma Industries share price and senior management changes

Alongside financial results, Sudarshan Pharma Industries also outlined leadership changes in the finance function. The company stated that Sachin Mehta will step down as Chief Financial Officer with effect from 1 May 2026. Mehta will, however, keep the position of Joint Managing Director, helping maintain continuity in key strategic decisions.

The board has started looking for a new individual to fill the CFO role that Mehta will vacate on 1 May 2026. Mehta is related to Chairman & Managing Director, Hemal Mehta. With Mehta staying on as Joint Managing Director, Sudarshan Pharma Industries aims to keep oversight of major plans with an experienced promoter during this transition.

Mehta has held the CFO position on several occasions. One of the recent terms ran from December 2023 to April 2025. In March 2025, Sudarshan Pharma Industries' board named Manoj Lodha as CFO. That decision was later rolled back, and Mehta continued in the combined role of Joint Managing Director and Chief Financial Officer until the current change.